WinstonWınston
Zeo ScientifiX logo

Zeo ScientifiX

ZEOX
Biotechnology · Healthcare
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Zeo ScientifiX is a small biotechnology company focused on developing treatments for rare diseases. Its pipeline centers on therapies targeting conditions with few or no existing treatment options, making patients with unmet medical needs its primary end market. The company operates in the specialty pharmaceutical and rare disease space, where small patient populations often allow for premium drug pricing.

Zeo ScientifiX generates revenue primarily through product sales and licensing arrangements, though its deeply negative operating margin signals it is still spending far more than it earns — a common stage for early-stage biotech firms. It operates mainly in the United States and carries a very small market capitalization, meaning it has limited financial resources compared to larger pharmaceutical peers. The company's main risk is its dependence on a narrow pipeline; if key clinical trials fail or regulatory approvals are delayed, the business could face serious funding pressure.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+32.7% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+40.0% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

53.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~6 months

$1M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Strong grower

Zeo ScientifiX is growing revenue at 33% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
80.6%
Premium pricing power — 80.6% gross margin
Operating Margin
-60.7%
Losing money on operations — -60.7%
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+15.9%
Fast-growing sales (15.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-23.2%
Burning cash (-23.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial